1513 — Livzon Pharmaceutical Income Statement
0.000.00%
Last trade - 00:00
- HK$26.50bn
- HK$20.21bn
- CNY12.43bn
- 91
- 72
- 98
- 99
2019 December 31st | 2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | CAS | CAS | CAS | CAS | CAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 9,385 | 10,520 | 12,064 | 12,630 | 12,430 |
Cost of Revenue | |||||
Gross Profit | 5,942 | 6,777 | 7,754 | 8,052 | 7,655 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 7,651 | 8,025 | 9,803 | 10,293 | 10,017 |
Operating Profit | 1,734 | 2,496 | 2,261 | 2,337 | 2,413 |
Gain / Loss on Sale of Assets | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 1,728 | 2,489 | 2,246 | 2,331 | 2,383 |
Provision for Income Taxes | |||||
Net Income After Taxes | 1,462 | 2,131 | 1,952 | 1,956 | 1,898 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 1,303 | 1,715 | 1,776 | 1,909 | 1,954 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 1,303 | 1,715 | 1,776 | 1,909 | 1,954 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 1.44 | 1.74 | 1.9 | 2.05 | 2.1 |
Dividends per Share |